Tacrolimus therapeutic drug monitoring and pediatric renal transplant graft outcomes

被引:17
|
作者
Larkins, Nicholas [1 ]
Matsell, Douglas G. [1 ]
机构
[1] Univ British Columbia, Dept Pediat, Div Nephrol, Vancouver, BC V6T 1W5, Canada
关键词
kidney transplantation; pediatric; tacrolimus; therapeutic drug monitoring; outcome; KIDNEY-TRANSPLANTATION; CALCINEURIN INHIBITORS; ACUTE REJECTION; EXPOSURE; CYCLOSPORINE; TOXICITY; FK506;
D O I
10.1111/petr.12369
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Predose monitoring of tacrolimus levels is standard practice in the care of pediatric renal transplant patients. This is despite a paucity of data investigating the ideal target range in children, and controversy as to whether tacrolimus levels correlate with renal transplant outcomes. We performed a retrospective cohort analysis of 48 renal transplant patients at a single Canadian pediatric transplant center following the initiation of a tacrolimus-mycophenolate-prednisone-based IS protocol. We analyzed the relationship of graft function, as defined by GFR up to fiveyr post-transplant, to the preceding mean tacrolimus level. There was no significant correlation between absolute GFR and mean tacrolimus levels (r=0.206, p=0.38). However, a higher mean tacrolimus level, particularly 10ng/mL in the first threemonths after transplantation, was associated with a slower rate of decline in GFR with time (r=0.608, p=0.004) and with a less likelihood of developing CKD fiveyr after transplant. We suggest that the optimal target range for tacrolimus levels may be at the upper end of what is currently practiced and that further research to validate these findings would be useful.
引用
收藏
页码:803 / 809
页数:7
相关论文
共 50 条
  • [41] Variation in Prescribing Patterns and Therapeutic Drug Monitoring of Intravenous Busulfan in Pediatric Hematopoietic Cell Transplant Recipients
    McCune, Jeannine S.
    Baker, K. Scott
    Blough, David K.
    Gamis, Alan
    Bemer, Meagan J.
    Kelton-Rehkopf, Megan C.
    Winter, Laura
    Barrett, Jeffrey S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03) : 264 - 275
  • [42] Therapeutic drug monitoring of tacrolimus after kidney transplantation: trough concentration or area under curve-based monitoring?
    van Gelder, Teun
    Gelinck, Armin
    Meziyerh, Soufian
    de Vries, Aiko P. J.
    Moes, Dirk Jan A. R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [43] Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients
    Hübner, GI
    Eismann, R
    Sziegoleit, W
    THERAPEUTIC DRUG MONITORING, 1999, 21 (05) : 536 - 539
  • [44] Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients
    Wang, Ping
    Mao, Yong
    Razo, Juan
    Zhou, Xiaobo
    Wong, Stephen T. C.
    Patel, Samir
    Elliott, Erin
    Shea, Erin
    Wu, Alan H. B.
    Gaber, A. Osama
    PHARMACOGENOMICS, 2010, 11 (10) : 1389 - 1402
  • [45] Usage of Tacrolimus and Mycophenolic Acid During Conception, Pregnancy, and Lactation, and Its Implications for Therapeutic Drug Monitoring: A Systematic Critical Review
    Le, Hoang Lan
    Francke, Marith, I
    Andrews, Louise M.
    de Winter, Brenda C. M.
    van Gelder, Teun
    Hesselink, Dennis A.
    THERAPEUTIC DRUG MONITORING, 2020, 42 (04) : 518 - 531
  • [46] Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients
    Cheng, Fang
    Wang, Jinglin
    Hu, Min
    Zeng, Fang
    Wang, Zhendi
    Zhang, Yu
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 1463 - 1474
  • [47] Placental disposition of the immunosuppressive drug tacrolimus in renal transplant recipients and in ex vivo perfused placental tissue
    Freriksen, J. J. M.
    Feyaerts, D.
    van den Broek, P. H. H.
    van der Heijden, O. W. H.
    van Drongelen, J.
    van Hamersvelt, H. W.
    Russel, F. G. M.
    van der Molen, R. G.
    Greupink, R.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 119 : 244 - 248
  • [48] Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients
    Gustavsen, Marte Theie
    Midtvedt, Karsten
    Robertsen, Ida
    Woillard, Jean-Baptiste
    Debord, Jean
    Klaasen, Rolf Anton
    Vethe, Nils Tore
    Bergan, Stein
    Asberg, Anders
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1327 - 1335
  • [49] Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations
    Henin, Emilie
    Govoni, Mirco
    Cella, Massimo
    Laveille, Christian
    Piotti, Giovanni
    ADVANCES IN THERAPY, 2021, 38 (10) : 5317 - 5332
  • [50] Association of graft survival with tacrolimus exposure and late intra-patient tacrolimus variability in pediatric and young adult renal transplant recipients-an international CTS registry analysis
    Gold, Annika
    Toenshoff, Burkhard
    Doehler, Bernd
    Suesal, Caner
    TRANSPLANT INTERNATIONAL, 2020, 33 (12) : 1681 - 1692